5 Results for "

Drug dependence

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "Drug dependence" in MCE Product Catalog:

Cat. No.: HY-W835175
CAS No.: 209185-99-9
Target:  

iGluR

Research Areas:  

Neurological Disease

Neramexane hydrochloride is an oral N-methyl-D-aspartate (NMDA) receptor antagonist, as a potential neuroprotectant for various central nervous system disorders, including Alzheimer's disease, and for the potential study of drug and alcohol dependence, and pain.
loading...
    loading...
Cat. No.: HY-158014
CAS No.: 1627576-64-0
Target:  

Dopamine Transporter

Research Areas:  

Neurological Disease

JJC8-089 is a dopamine transporter (DAT) inhibitor that may improve motivational dysfunction and increase effortful behavior in goal-directed activities. JJC8-089 significantly reversed the low-effort effects induced by the VMAT-2 inhibitor Tetrabenazine (HY-B0590) in rats and increased the choice of high-effort fixed-ratio 5-bar presses versus food intake. .
loading...
    loading...
Cat. No.: HY-138973
CAS No.: 219810-59-0
Target:  

iGluR

Research Areas:  

Neurological Disease

Neramexane is an oral N-methyl-D-aspartate (NMDA) receptor antagonist, as a potential neuroprotectant for various central nervous system disorders, including Alzheimer's disease, and for the potential treatment of drug and alcohol dependence, and pain.
loading...
    loading...
Cat. No.: HY-121057
CAS No.: 67739-71-3
Synonyms: 3-OH FNTZ
Research Areas:  

Metabolic Disease

3-Hydroxyflunitrazepam (3-OH FNTZ) is the major metabolite of Flunitrazepam (FNTZ), generated via 3-hydroxylation by CYP3A4 (Km = 286 μM), and represents the dominant metabolic pathway (>80%) in liver microsomes. Its formation is significantly inhibited by CYP3A4 inhibitors such as Ketoconazole (HY-B0105) (IC50 = 0.11 μM) and Ritonavir (HY-90001) (IC50 = 0.041 μM), indicating a strong dependence on CYP3A4 activity and potential drug interactions .
loading...
    loading...
Cat. No.: HY-159924
CAS No.: 2131200-75-2
Target:  

Opioid Receptor

Research Areas:  

Neurological Disease

DBPR116 is a prodrug of BPRMU191 (HY-159923) with blood-brain barrier penetration capability. DBPR116 significantly improves the delivery of centrally targeted drugs. In combination with the antagonist Naltrexone (HY-76711), DBPR116 demonstrated superior safety and analgesic efficacy compared to morphine in various in vivo pharmacological studies, including thermal pain models, cancer pain models, constipation, sedation, psychological dependence, heart rate, and respiratory frequency. As a prodrug strategy for peripheral administration, DBPR116 effectively alleviates pain while reducing adverse effects, showing potential as a safer opioid analgesic .
loading...
    loading...